Quick Answer
Mereo BioPharma Group plc reported Total Revenue of $500.0 thousand for fiscal year 2025.
Mereo BioPharma Group plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $500.0K | $0.00 -100.0% |
$10.00M | $0.00 | — | — |
| Net Income | -$41.88M +3.2% |
-$43.25M -46.8% |
-$29.47M +30.2% |
-$42.22M | — | — |
| Diluted EPS | -$0.05 +16.7% |
-$0.06 -50.0% |
-$0.04 +42.9% |
-$0.07 | — | — |
| Total Assets | $45.92M -39.9% |
$76.39M +14.9% |
$66.50M -14.1% |
$77.41M -38.8% |
$126.42M +100.8% |
$62.95M -27.2% |
| Cash and Equivalents | $40.99M -41.3% |
$69.80M +21.6% |
$57.42M -15.8% |
$68.18M | — | — |
| Stockholders Equity | $40.92M -32.9% |
$60.97M +20.6% |
$50.54M -1.7% |
$51.40M -44.2% |
$92.20M | — |
| R&D Expense | $17.77M -15.1% |
$20.93M +20.2% |
$17.42M -40.9% |
$29.46M +25.1% |
$23.56M +44.1% |
$16.35M -30.8% |
| Operating Income | -$40.11M +15.3% |
-$47.36M -66.7% |
-$28.42M +47.8% |
-$54.43M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | -100.0% |
| Net Income | September 30, 2025 | -$7.02M | +53.2% | +51.9% |
| Diluted EPS | September 30, 2025 | -$0.01 | +50.0% | +50.0% |
| Total Assets | September 30, 2025 | $53.60M | -39.6% | -14.4% |
| Cash and Equivalents | September 30, 2025 | $48.70M | -39.5% | -13.2% |
| Stockholders Equity | September 30, 2025 | $46.60M | +164.2% | -14.0% |
| R&D Expense | September 30, 2025 | $4.27M | +34.7% | -20.5% |
| Operating Income | September 30, 2025 | -$10.02M | -6.8% | +4.6% |
- Mereo BioPharma Group plc reported Total Revenue of $500.0 thousand for fiscal year 2025.
- Mereo BioPharma Group plc reported Net Income of -$41.88 million for fiscal year 2025.
- Mereo BioPharma Group plc showed an increase of +3.2% in Net Income compared to the prior fiscal year.
- Mereo BioPharma Group plc reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
- Mereo BioPharma Group plc showed an increase of +16.7% in Diluted EPS compared to the prior fiscal year.
- Mereo BioPharma Group plc reported Total Assets of $45.92 million for fiscal year 2025.
- Mereo BioPharma Group plc showed a decrease of -39.9% in Total Assets compared to the prior fiscal year.
- Mereo BioPharma Group plc reported Cash and Equivalents of $40.99 million for fiscal year 2025.
- Mereo BioPharma Group plc showed a decrease of -41.3% in Cash and Equivalents compared to the prior fiscal year.
- Mereo BioPharma Group plc reported Stockholders Equity of $40.92 million for fiscal year 2025.
- Mereo BioPharma Group plc showed a decrease of -32.9% in Stockholders Equity compared to the prior fiscal year.
- Mereo BioPharma Group plc reported R&D Expense of $17.77 million for fiscal year 2025.
- Mereo BioPharma Group plc showed a decrease of -15.1% in R&D Expense compared to the prior fiscal year.
- Mereo BioPharma Group plc reported Operating Income of -$40.11 million for fiscal year 2025.
- Mereo BioPharma Group plc showed an increase of +15.3% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: